|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/19 | |
| A61K 31/4412 | |||
| A61K 35/768 | |||
| A61P 35/04 | |||
| A61K 31/44 |
| (11) | Number of the document | 2477499 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10816293.4 |
| Date of filing the European patent application | 2010-09-14 | |
| (97) | Date of publication of the European application | 2012-07-25 |
| (45) | Date of publication and mention of the grant of the patent | 2018-04-11 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2010/048829 |
| Date | 2010-09-14 |
| (87) | Number | WO 2011/032180 |
| Date | 2011-03-17 |
| (30) | Number | Date | Country code |
| 242238 P | 2009-09-14 | US | |
| 244250 P | 2009-09-21 | US |
| (72) |
KIRN, David, US
BREITBACH, Caroline, US
|
| (73) |
SillaJen Biotherapeutics, Inc.,
450 Sansome Street, Suite 650, San Francisco, CA 94111,
US
|
| (54) | ONCOLYTIC VACCINIA VIRUS COMBINATION CANCER THERAPY |
| ONCOLYTIC VACCINIA VIRUS COMBINATION CANCER THERAPY |